Medicine
Ramipril 1.25 mg capsule
Ramipril 1.25 mg capsule is a generic prescription medicine for oral use, made by 8 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20 • C to 25 • C (68 • F to 77 • F).
Key facts
- Active ingredient (INN)
- Ramipril
- Brand
- Sold under the generic name
- Strength
- 1.25 mg
- Dosage form
- Capsule
- Route
- Oral
- Packs
- 100 capsules, 500 capsules, 30 capsules and 19 more
- Manufacturers
- Zydus LifesciencesIndiaAurobindo PharmaIndiaChartwell RXRising Pharma HoldingsBluePoint LaboratoriesExelan PharmaceuticalsHikma Pharmaceuticals8 labelers on the register
- Origin register
- US FDA, United States
- Storage
- Store at 20 • C to 25 • C (68 • F to 77 • F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- C09AA05 Ramipril
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 10 June 2008
- Identifiers
- RxCUI 198188, 198189, 261962 +1DailyMed set ID 496b346b-ca79-4483-a950-bed9464e6a9d, 055bb582-67cd-425a-8823-d543c14305ce, 1e1dfacf-b831-4743-a874-9a5e5ef8a120 +6NDC 65841-655, 68382-144, 76282-670 +6Application ANDA078832, ANDA077900, ANDA091604 +2
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
Packs from every labeler of this generic presentation.
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 100 capsule in 1 bottle | 65841-655-01 | Zydus LifesciencesIndia | 20 November 2010 |
| 500 capsule in 1 bottle | 65841-655-05 | Zydus LifesciencesIndia | 20 November 2010 |
| 30 capsule in 1 bottle | 65841-655-06 | Zydus LifesciencesIndia | 20 November 2010 |
| 90 capsule in 1 bottle | 65841-655-16 | Zydus LifesciencesIndia | 20 November 2010 |
| 10 blister pack in 1 carton / 10 capsule in 1 blister pack | 65841-655-30 | Zydus LifesciencesIndia | 20 November 2010 |
| 100 capsule in 1 bottle | 68382-144-01 | Zydus LifesciencesIndia | 20 November 2010 |
| 500 capsule in 1 bottle | 68382-144-05 | Zydus LifesciencesIndia | 20 November 2010 |
| 30 capsule in 1 bottle | 68382-144-06 | Zydus LifesciencesIndia | 20 November 2010 |
| 90 capsule in 1 bottle | 68382-144-16 | Zydus LifesciencesIndia | 20 November 2010 |
| 100 blister pack in 1 carton / 1 capsule in 1 blister pack | 68382-144-77 | Zydus LifesciencesIndia | 20 November 2010 |
| 100 capsule in 1 bottle | 65862-474-01 | Aurobindo PharmaIndia | 8 June 2011 |
| 10 blister pack in 1 carton / 10 capsule in 1 blister pack | 65862-474-10 | Aurobindo PharmaIndia | 8 June 2011 |
| 30 capsule in 1 bottle | 65862-474-30 | Aurobindo PharmaIndia | 8 June 2011 |
| 1000 capsule in 1 bottle | 65862-474-99 | Aurobindo PharmaIndia | 8 June 2011 |
| 100 capsule in 1 bottle | 62135-271-01 | Chartwell RX | 26 August 2020 |
| 30 capsule in 1 bottle | 62135-271-30 | Chartwell RX | 26 August 2020 |
| 90 capsule in 1 bottle | 62135-271-90 | Chartwell RX | 2 January 2026 |
| 100 capsule in 1 bottle | 76282-670-01 | Exelan Pharmaceuticals | 28 January 2020 |
| 100 capsule in 1 bottle | 0054-0106-25 | Hikma Pharmaceuticals | 18 June 2008 |
| 100 capsule in 1 bottle | 57237-222-01 | Rising Pharma Holdings | 8 June 2011 |
| 30 capsule in 1 bottle | 57237-222-30 | Rising Pharma Holdings | 8 June 2011 |
| 100 capsule in 1 bottle | 68001-428-00 | BluePoint Laboratories | 28 February 2020 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 28 January 1991 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Ramipril
Clinical summary
Ramipril is an angiotensin converting enzyme inhibitor indicated for the treatment of hypertension, to lower blood pressure, among other approved uses. It is available as capsules for oral use. MedsAcross supplies Ramipril for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about RamiprilFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Ramipril prescribing information (Rising Pharma Holdings) · U.S. National Library of Medicine, DailyMed
Need Ramipril 1.25 mg capsule for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.